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Abstract: The skin secretions of the subfamily Phyllomedusinae have long been known to contain a
number of compounds with antimicrobial potential. Herein, a biosynthetic dermaseptin-precursor
cDNA was obtained from a Phyllomedusa sauvagii skin secretion-derived cDNA library, and thereafter,
the presence of the mature peptide, namely dermaseptin-PS3 (DPS3), was confirmed by LC–MS/MS.
Moreover, this naturally occurring peptide was utilized to design two analogues, K5, 17-DPS3
(introducing two lysine residues at positions 5 and 17 to replace acidic amino acids) and L10, 11-DPS3
(replacing two neutral amino acids with the hydrophobic amino acid, leucine), improving its
cationicity on the polar/unipolar face and hydrophobicity in a highly conserved sequence motif,
respectively. The results in regard to the two analogues show that either increasing cationicity,
or hydrophobicity, enhance the antimicrobial activity. Also, the latter analogue had an enhanced
anticancer activity, with pretreatment of H157 cells with 1 µM L10, 11-DPS3 decreasing viability
by approximately 78%, even though this concentration of peptide exhibited no haemolytic effect.
However, it must be noted that in comparison to the initial peptide, both analogues demonstrate
higher membrane-rupturing capacity towards mammalian red blood cells.
Keywords: antimicrobial peptide (AMP); dermaseptin; anuran skin secretion; drug design;
antimicrobial activity; anticancer activity
Key Contribution: This study reports the identification of a naturally occurring AMP, dermaseptin,
from skin secretions and examines its potential biological activity. It also aims to improve the
biological activity (e.g., antimicrobial and anticancer effects) via optimization of the peptide’s cationic
or hydrophobic properties through residue substitutions.
1. Introduction
Of the many anuran skin-derived peptides that are known, dermaseptin and dermaseptin-like
peptides are the most remarkable candidates for developing new antibiotics in Hylidae frogs [1–3].
Although there is much heterogeneity in either the peptide sequence, or length, among dermaseptins,
the family nevertheless shares several common structural characteristics, including Trp at position
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3 and a conserved sequence of AA(G)KAALG(N)A in the mid-region [4]. In addition, dermaseptins
commonly possess a high propensity to adopt an α-helical conformation in hydrophobic media,
since the first dermaseptin peptide with 80% of α-helical conformation was isolated from Hylidae
frogs [3,5,6]. Pharmacologically, apart from broad-spectrum antimicrobial activity (e.g., dermaseptin S4
and B), haemolytic activity and anticancer activity have been reported (dermaseptin-PH and B2) [3,7,8].
Numerous studies indicate that the net charge is a key factor influencing the binding of AMPs to
membranes, as AMPs bind to the membrane by electrostatic interaction and competitively replace the
divalent cation [9–11]. Therefore, it is believed that changing the number of positive charges present
in an AMP can likely change its membrane binding ability, resulting in a change in antimicrobial
activity. Also, in general, approximately half of AMP amino acid residues are hydrophobic, and their
hydrophobicity and their activity can be altered by changing the number of Leu, Ile and Val residues
in these peptides. However, both antibacterial and haemolytic activities of these AMPs tend to get
increased simultaneously by increasing the hydrophobicity, due to the fact that the hydrophobic groups
play a key role in their insertion into the cell membrane [10].
Herein, we describe the discovery of a biosynthetic precursor, preprodermaseptin, encoding an
antimicrobial peptide, DPS3, from the skin secretion of Phyllomedusa sauvagii using a combination of
shotgun cloning and mass spectrometry. The corresponding chemically synthesised replicate exerted
weak antibacterial activity towards pathogenic microorganisms and weak cytotoxic activity towards
tumour cells. Therefore, we designed two analogues of this naturally occurring peptide, K5, 17-DPS3
and L10, 11-DPS3, to potentially optimize its cationicity on the polar/unipolar face and hydrophobicity
in conserved sequence motif of dermaseptin, respectively.
2. Results
2.1. Molecular Cloning of a DPS1 Precursor cDNA from a Skin Secretion-Derived cDNA Library
Using the shotgun cloning strategy, the nucleotide sequence of a full-length biosynthetic
precursor-encoding cDNA was consistently cloned among the artificially reconstructed cutaneous
secretion-derived cDNA library from Phyllomedusa sauvagii. More specifically, the domain architecture
of this preprodermaseptin transcript (Figure 1) compromises 70 amino acid residues, encoding a
single copy of a peptide termed DPS3, where the C-terminus was subjected to post-translational
modification with carboxyl-terminal amide formation. From the translated open reading frame, the KR
is a typical convertase processing site in vivo and the resulting mature peptide consisted of 23 amino
acid residues (ALWKDILKNAGKAALNEINQIVQ-amide). The cDNA precursor was deposited in
GenBank database under an accession no. of MH536746.Toxins 2018, 10, x FOR PEER REVIEW  3 of 12 
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absorbance peak by an arrow that corresponds to DPS3. 
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Figure 1. Nucleotide and translat d pen reading f am amino acid sequence of the cDNA encoding the
biosynthetic precursor of a novel peptide from the skin secretion of Phyllomedusa sauvagii. The putative
N-terminal signal peptide sequence is double-underscored, putative mature peptide sequence is
single-underscored and an asterisk indicates the stop codon.
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2.2. Isolation and Structural Characterisation of DPS3
The predicted amino acid sequence identified via cDNA cloning suggested the existence of a
peptide in the skin secretion of Phyllomedusa sauvagii, so the lyophilized skin secretion was directly
analysed to determine if this peptide was present. The presence of the mature DPS3 peptide was
confirmed by RP–HPLC isolation, with the retention time at approximately 108 min, and MS/MS
fragmentation sequencing (Figure S1, Figure 2 and Table 1, respectively).
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Figure 2. Region of RP–HPLC chromatogra of Phyllomedusa sauvagii skin secretion indicating the
absorbance peak by an arrow that corresponds to DPS3.
Table 1. Predicted b-ion and y-ion MS/MS fragment ion series (singly and doubly charged) of DPS3.
The observed ions are indicated by single-underlined. The unit for MS data is m/z.
#1 b (1+) b (2+) Seq. y (1+) y (2+) #2
1 72.04440 36.52584 A 23
2 185.12847 93.06787 L 2478.41923 1239.71325 22
3 371.20779 186.10753 W 2365.33516 1183.17122 21
4 499.30276 250.15502 K 2179.25584 1090.13156 20
5 614.32971 307.66849 D 2051.16087 1026.08407 19
6 727.41378 364.21053 I 1936.13392 968.57060 18
7 840.49785 420.75256 L 1823.04985 912.02856 17
8 968.59282 484.80005 K 1709.96578 855.48653 16
9 1082.63575 541.82151 N 1581.87081 791.43904 15
10 1153.67287 577.34007 A 1467.82788 734.41758 14
11 1210.69434 605.85081 G 1396.79076 698.89902 13
12 1338.78931 669.89829 K 1339.76929 670.38828 12
13 1409.82643 705.41685 A 1211.67432 606.34080 11
14 1480.86355 740.93541 A 1140.63720 570.82224 10
15 1593.94762 797.47745 L 1069.60008 535.30368 9
16 1707.99055 854.49891 N 956.51601 478.76164 8
17 1837.03315 919.02021 E 842.47308 421.74018 7
18 1950.11722 975.56225 I 713.43048 357.21888 6
19 2064.16015 1032.58371 N 600.34641 300.67684 5
20 2192.21873 1096.61300 Q 486.30348 243.65538 4
21 2305.30280 1153.15504 I 358.24490 179.62609 3
22 2404.37122 1202.68925 V 245.16083 123.08405 2
23 Q-Amidated 146.09241 73.54984 1
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2.3. Physicochemical Properties and Secondary Structures of DPS1 and Its Analogues
Both DPS3 and L10, 11-DPS3 possessed the same net positive charge of +2, which increased to +6
in the case of the cationicity-enhanced analogue (Table 2). Additionally, DPS3 and K5, 17-DPS3 had
a similar degree of hydrophobicity, which was increased in L10, 11-DPS3. The helical wheel projects
showed that DPS3 and its analogues have the same direction of summed vectors of hydrophobicity
(Figure 3). Meanwhile, K5, 17-DPS3 had one more positive charge on both hydrophilic and hydrophobic
faces than the other two analogues, and L10, 11-DPS3 showed an enlarged hydrophobic face. Also,
although these three peptides existed in random coils in aqueous solution, they all adopted α-helical
conformations in membrane-mimicking solution, presenting obviously negative peaks at 222 nm and
208 nm, with the natural peptide presenting the largest proportion of α-helical domain (44.9% of its
secondary structure) (Figure 3 and Table 2).
Table 2. Physicochemical properties of DPS3 and its two analogues.
Peptide Hydrophobicity(H)
Hydrophobic
Moment (µH) % Helix
1 Net Charge
ALWKDILKNAGKAALNEIN
QIVQ-NH2
0.373 0.437 44.9 +2
ALWKKILKNAGKAALNKIN
QIVQ-NH2
0.349 0.437 39 +6
ALWKDILKNLLKAALNEIN
QIVQ-NH2
0.508 0.517 28.8 +2
1 In 50% 2,2,2-trifluoroethanol (TFE)/10 mM ammonium acetate (NH4Ac) solution.Toxins 2018, 10, x FOR PEER REVIEW  5 of 12 
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2.4. Antimicrobial Activity
The parent peptide, DPS3, generally showed weak antimicrobial activity, although it did exhibit
better activity against Gram-negative bacteria. As expected, when compared to the parent peptide, both
artificial analogues displayed enhanced antimicrobial activity against all the microorganisms examined
(Table 3). In particular, K5, 17-DPS3 displayed MIC values of 8 µM or less against Gram-positive
(Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria, as well as yeast (Candida albicans).
Table 3. Antimicrobial activity of the parent DPS3 peptide and its two analogues against
various microorganisms.
Microorganisms
DPS3 K5, 17-DPS3 L10, 11-DPS3
MIC (µM)
S. aureus (NCTC 10788) 256 8 8
E. coli (NCTC 10418) 32 8 16
C. albicans (NCYC 1467) 64 4 16
2.5. Cytotoxicity of Peptides on Human Cancer and Normal Cells
DPS3 and its two artificial analogues all exhibited inhibitory effects on the proliferation of the two
tested human cancer cell lines and normal cell line (Figure 4). Increasing the cationicity of the parent
peptide had no significant influence on its antiproliferative activity, whereas altering its hydrophobicity
markedly enhanced its antiproliferative activity, with this peptide exhibiting an IC50 value more than
10-fold lower than either of the other peptides (Table 4).
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Table 4. Induced cytotoxicity of DPS3 and analogues on the human cancer cells. IC50s were calculated
from the normalized curves in Figure 4 using GraphPad Prism 6 (GraphPad Software, USA).
Peptide IC50 for H157 (µM) IC50 for PC3 (µM) IC50 for HMEC-1 (µM)
DPS3 15.67 18.20 132.10
K5, 17-DPS3 18.20 18.20 123.00
L10, 11-DPS3 0.12 1.85 8.76
2.6. Haemolysis Activity
All three peptides exhibited some haemolytic activity against healthy red blood cells (Figure 5).
However, both artificial analogues exhibited a greater effect than the parent peptide, with the
L10, 11-DPS3 analogue showing marked haemolysis even at lower concentrations. The HC50s of
DPS3, K5, 17-DPS3 and L10, 11-DPS3 are 138.1, 14.98 and 3.44, respectively.
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3. Discussion
Typically, most naturally occurring dermaseptins are 28 to 34 amino acid residues in length [12–14],
therefore, the 23-mer DPS3 reported here is relatively short for this family. Huang and colleagues have
previously isolated a similar-length dermaseptin, dermaseptin-PH [3]. Compared with other similar
dermaseptins, the antimicrobial activity of DPS3 and dermaseptin-PH indicate that these two native
truncated dermaseptins are less potent as AMPs than other longer dermaseptin peptides, possibly
suggesting increasing peptide length in this family is potentially related to a higher antimicrobial
activity. Besides, the physicochemical properties, including charge and hydrophobicity, are the
main factors affecting antimicrobial activity, and therefore they are considered as one of the design
parameters to optimize in AMPs [7,15–17]. In terms of the antibacterial mechanism of action of
AMPs, it is mostly thought to concern the electrostatic interaction and hydrophobic engagement
between AMPs and bacterial cell membranes [18]. Compared with other members of the dermaseptin
family (Figure S2), DPS3 shares sequence similarities and they are canonical cationic and α-helical
amphipathic peptides [1,3,5,8,19,20]. Besides, the conformational transition feature from coil to helix
upon binding to lipid bilayers, in general, concerns a membrane-damaging mode of action in the
dermaseptin family. In particular, the polycationic properties, as well as a large number of hydrophobic
amino acids in the primary structure, and conformational alternation from random coil to helical
frame among dermaseptins, along with their membrane-lytic activity, suggest their mechanism of
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action is likely to involve membrane disruption. Indeed, previous studies have found leakage and
morphological alterations in the artificial bacterial membrane after treatment with fluorescent-labelled
dermaseptins [21,22]. More recently, using the electron microscopy, a dermaseptin peptide, DS1, was
found to distort the cell wall surface, proposing that the cytolysis or cell membrane disruption of
C. albicans eventually cause cell death [23].
Early research has revealed a strong correlation between α-helical domain and antimicrobial
activity, involving the local fusion of the membrane leaflets, pore formation, cracks, as well as the
depth of membrane insertion [24–26]. Also, the α-helical conformation of dermaseptins is normally
considered as one of the main factors in the hydrophobic interaction of AMPs and lipid layer [24,26].
In our investigation, the CD spectra of the three peptides showed that the amount of helical
conformation is similar across all three. Our results indicate that an increase in antimicrobial activity
can be achieved via optimization of cationic or hydrophobic properties of the dermaseptin peptides
through residue substitution. However, both artificial analogues induced more haemolysis than the
parent peptide, though K5, 17-DPS3 showed minimal haemolysis at the concentrations that exhibited
antimicrobial activity, indicating it could still represent an interesting AMP. It is often supposed that the
electrostatic interaction between anionic molecules (such as LPS, teichoic acids or acidic phospholipids)
and positively charged AMPs is an essential step allowing the cationic peptides to selectively aggregate
on the bacterial membrane; therefore, it is also believed that changing the number of positive
charges present in an AMP can likely change its membrane binding ability [9–11]. Also, the selective
interactions between lysine/arginine residues and anionic lipid membranes and reduced selectivity
upon increasing hydrophobic properties of antimicrobials have been supported by X-ray scattering
data [27,28]. We speculate that the cationicity-enhanced analogue shows more sensitive membrane
binding ability towards bacterial cells than mammalian cells, therefore resulting in less haemolysis.
The electrical attraction of these peptides to the membrane is important for their antimicrobial activity,
and this could explain why the cationicity-enhanced analogue shows more potent antimicrobial activity
than L10, 11-DPS3, but less haemolysis. Similarly, K4K20-S4, a dual lysine-substituted dermaseptin-S4,
also shown increased antimicrobial activity, along with two-fold haemolytic potency and higher
lipophilic affinity [29]. Previously, 2D-NMR has shown that the consensus motif AA(G)KAALG(N)
among dermaseptins is adopting a well-defined α-helical structure [1,7]. Herein, we enhanced the
hydrophobicity in this highly conserved motif with amphipathic α-helix and found more potent
cytolytic action towards mammalian erythrocytes. On the other hand, as the hydrophobicity is
important for membrane disruption, increasing the hydrophobicity could improve the peptides’
ability to disrupt membranes, but not in a way that favours microorganism selectivity. In this regard,
we proposed that it possibly results from stronger hydrophobic interaction within the core of the
bacterial membrane. Taken together, the data presented indicate that it is possible to improve the
membrane-lytic activity of these AMPs without increasing the peptide length.
DPS3, and its analogues, all exhibit antiproliferative effects on the tested cancer cells, although
L10, 11-DPS3 exhibited an enhanced antiproliferative impact. Recent studies have shown that cancer
cell membranes, similar to the bacterial membrane, carry a negative charge due to overexpression of
anionic molecules, such as phosphatidylserine, sialic acid and glycosaminoglycans (GAGs) [7,17,18].
Therefore, although it is unclear how the dermaseptins mediate their anticancer activity, it could
result from their interaction with and disruption of the cell membrane, similar to their antimicrobial
action. However, dermaseptins have been found to interact with, and aggregate on, the surface
of cancer cells, as well as being able to penetrate into cancer cells, without compromising the cell
membrane [8,14,19,22]. Also, Dos Santos and colleagues found that an Alexa- and biotin-labelled
version of the dermaseptin peptide, DRS-B2, could internalise into cancer cells, and implicated
its non-protein binding partner GAGs, suggesting GAGs are possibly involved in dermaseptin
internalization [8]. Notably, the viability of H157 cells pretreated with L10, 11-DPS3 (1 µM) decreased
by approximately 78%, whilst no membrane lysis was observed in mammalian erythrocytes exposed
to the same concentration of peptide, possibly suggesting that a nonlytic mechanism may be involved,
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at least at lower concentrations. At higher peptide concentrations (>1 µM), the higher anticancer cell
impact is consistent with increasing haemolysis activity, suggesting that this is possibly due to cell
membrane disruption. However, further investigations will be needed to confirm this further.
4. Conclusions
The 23-mer peptide DPS3 reported here is relatively short in comparison to other naturally
occurring dermaseptins, which are commonly 28 to 34 amino acids. Although DPS3 exhibited relatively
weak bioactivity for dermaseptin family members, we rationally designed two DPS3 analogues with
the aim of improving its bioactivity. In particular, K5, 17-DPS3 and L10, 11-DPS3 both exhibited more
potent antimicrobial activity, whilst L10, 11-DPS3 also exhibited enhanced anticancer activity, even at
concentrations that had minimal impact upon healthy mammalian cells. This would suggest that
K5, 17-DPS3 and L10, 11-DPS3 may have promise as antimicrobial agents, and L10, 11-DPS3 could have
potential as an anticancer agent. However, further investigations will be required to determine the
exact mode of action that these peptides utilise against the microbial and cancer cells.
5. Materials and Methods
5.1. Acquisition of Phyllomedusa sauvagii Dermal Secretions
Three specimens of Phyllomedusa sauvagii (4–6 cm snout-to-vent length) obtained from a
commercial source in the United States were exposed to 12 h of light at 20–25 ◦C daily, and multivitamin
-loaded crickets were provided as the fodder three-times/week. Following four-month breeding,
dermal secretions were collected via surface electrical stimulation [30]. In summary, the skin surface
was moistened with deionized water, followed by mild transdermal electric stimulation (5 V, 100 Hz,
140 ms pulse width). Finally, the secretions were collected by gently flushing the frog skin with
deionized water, and they were lyophilized and stored at −20 ◦C until mRNA extraction. Animal
procedure was performed according to the guidelines in the UK Animal (Scientific, Procedures) Act
1986, project license PPL 2694, issued by the Department of Health, Social Services and Public Safety,
Northern Ireland. Procedures had been vetted by the IACUC of Queen’s University Belfast, and
approved on 1 March 2011.
5.2. Shotgun Cloning of a cDNA Encoding DPS1 Peptide Biosynthetic Precursor
The shotgun cloning employed the rapid amplification of cDNA ends (RACE) technique with a
degenerate primer, which has been described previously [31]. Briefly, the mRNA from the skin secretion
of Phyllomedusa camba was reverse-transcript to the cDNA library. The 3′-RACE was conducted
using the cDNA library and the primer (5′-ACTTTCYGAWTTRYAAGMCCAAABATG-3′) that was
designed to a segment of the 5′-untranslated region of cDNAs from Phyllomedusa species (accession
nos. AJ251876, AJ005443). The RACE products were subjected to purification and cloned, and finally
sequenced by the ABI 3100 Automatic Capillary Sequencer.
5.3. Identification and Analysis of Amino Acid Sequence
The identification of DPS1 from the skin secretion was performed according to our previous
study [31]. Briefly, 5 mg of lyophilized skin secretion was separated using the RP–HPLC column
(Jupiter C-18 250 mm × 10 mm, Phenomenex, Macclesfield, UK). The fraction was collected every
minute and then analyzed using MALDI–TOF MS (Perseptive Biosystems, Voyager DE, Perseptive
Biosystems, Framingham, MA, USA) and LCQ-Fleet ion-trap MS for sequencing (Thermo Fisher
Scientific, San Francisco, CA, USA).
5.4. Design and Synthesis of DPS1 and Its Two Analogues
To investigate the effect of the increasing cationicity and hydrophobicity, the peptide
DPS3 was used as the framework to design two analogues where the two acidic amino
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acids (at positions 5 and 17) and two neutral amino acid residues (at positions 10 and
11) were substituted with lysine and leucine residues, respectively. Accordingly, theses
analogues are named K5, 17-DPS3 (ALWKKILKNAGKAALNKINQIVQ-NH2) and L10, 11-DPS3
(ALWKDILKNLLKAALNEINQIVQ-NH2). The mean hydrophobicity, hydrophobic moment and
helical wheel projections of peptides were predicted by Heliquest (http://heliquest.ipmc.cnrs.fr/).
Peptide synthesis was carried out using Tribute peptide synthesizer (Protein Technologies, Tucson, AZ,
USA) along with Rink amide resin and standard Fmoc chemistry, which was described in a previous
study [32].
5.5. CD Analysis of Synthetic Peptides
The secondary structure was determined by a CD spectrometer (Jasco J851, Tokyo, Japan).
The analysis method was performed as previous study [32]. The obtained spectra were analysed by
the BeStSel CD online analysis program (http://bestsel.elte.hu [33]) to calculate the proportion of
α-helical conformation of each peptide.
5.6. Antimicrobial Assays
The antimicrobial activity of three peptides was evaluated via the minimal inhibitory
concentrations (MICs) against S. aureus (NCTC 10788), E. coli (NCTC 10418) and C. albicans (NCYC
1467) [32]. Microorganisms were inoculated with peptide (1 to 512 µM) in a 96-well plate and
determined at 550 nm using a Synergy HT plate reader (Biotech, Winooski, VT, USA).
5.7. Cell Viability of Human Cancer and Normal Cells
Cell viabilities were achieved using a typical MTT assay [32]. Briefly, non-small cell lung cancer
cell line, H157, human prostate carcinoma cell line, PC-3, and dermal microvascular endothelium
cell line, HMEC-1, were treated with synthesized peptides from 10−4 to 10−9 M. After adding MTT,
the formazan crystals were dissolved and read by the plate reader at 570 nm.
5.8. Haemolysis Assay
The haemolytic activity of each peptide was determined using a 2% suspension of horse blood
cells (supplied by TCS Biosciences Ltd., Buckingham, UK) as previous study [32]. The red blood
cell suspension was treated by the peptide (512−1 µM) at 37 ◦C for 2 h. The release of haemoglobin
detected by the plate reader at λ550 nm. 1% Triton X-100 and PBS were applied as the positive and
negative controls, respectively.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/10/8/320/s1,
Figure S1: Annotated fragment ion spectrum of DPS3, Figure S2: Alignment of amino acid sequences of DPS3 and
other dermaseptins.
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